Compare Ascendis Pharma A/S (ASND) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bitdeer Technologies Group — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Bitdeer Technologies Group trades at $12.98 (market cap $3.23B). The key difference: Ascendis Pharma A/S is far larger — about 5.5× Bitdeer Technologies Group's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| ASND | BTDR | |
|---|---|---|
Market Cap | $17.74B | $3.23B |
Sector | Health | Technology |
52-Week High | $277.18 | $25.90 |
52-Week Low | $163.32 | $7.28 |
Enterprise Value | $18.11B | $5.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BTDR trades at $13.29, down 7.26% in the last 24 hours, with a bearish technical signal and recent earnings misses. The company reported revenue growth to $620.25 million in 2025 but a net income margin of -26.96% in 2026, indicating profitability challenges. Positive developments include expansion into AI cloud infrastructure and new facility openings, yet negative cash flow from operations persists.
The outlook is mixed: strong analyst buy consensus (81.82%) and a $23.40 price target suggest upside, but operational losses and Bitcoin market volatility pose significant risks. Investment opportunity lies in AI infrastructure growth, while execution and sector headwinds require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
